Proposal of a Cutaneous Lupus Erythematosus-like Keratinocyte Model In vitro Under Local Conditions Using Interferon-alpha and Poly I:C and Its Use in Examining the Therapeutic Effects of Tyrosine Kinase 2 Inhibitor
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Kuba-Fuyuno Y, Kido-Nakahara M, Tsuji G, Sakai S, Nakahara T J Dermatol. 2024; 51(7):1031-1033.
PMID: 38831616 PMC: 11483919. DOI: 10.1111/1346-8138.17318.
References
1.
Kuba-Fuyuno Y, Kido-Nakahara M, Tsuji G, Sakai S, Nakahara T
. Proposal of a cutaneous lupus erythematosus-like keratinocyte model in vitro under local conditions using interferon-alpha and Poly I:C and its use in examining the therapeutic effects of tyrosine kinase 2 inhibitor. J Dermatol. 2024; 51(7):1031-1033.
PMC: 11483919.
DOI: 10.1111/1346-8138.17318.
View
2.
Nurnberg W, Haas N, Schadendorf D, Czarnetzki B
. Interleukin-6 expression in the skin of patients with lupus erythematosus. Exp Dermatol. 1995; 4(1):52-7.
DOI: 10.1111/j.1600-0625.1995.tb00222.x.
View
3.
Sarkar M, Hile G, Tsoi L, Xing X, Liu J, Liang Y
. Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa. Ann Rheum Dis. 2018; 77(11):1653-1664.
PMC: 6185784.
DOI: 10.1136/annrheumdis-2018-213197.
View
4.
Scholtissek B, Zahn S, Maier J, Klaeschen S, Braegelmann C, Hoelzel M
. Immunostimulatory Endogenous Nucleic Acids Drive the Lesional Inflammation in Cutaneous Lupus Erythematosus. J Invest Dermatol. 2017; 137(7):1484-1492.
DOI: 10.1016/j.jid.2017.03.018.
View
5.
Morand E, Pike M, Merrill J, van Vollenhoven R, Werth V, Hobar C
. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2022; 75(2):242-252.
PMC: 10100399.
DOI: 10.1002/art.42391.
View